Drug intelligence / Profile preview

CD19-BCMA UCAR-T

Development stage: Unknown
Lead developer: T-MAXIMUM Biopharmaceuticals
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Injection

Overview

CD19-BCMA UCAR-T is a Universal Chimeric Antigen Receptor T-cell (UCAR-T) therapy engineered to simultaneously target two distinct antigens: B-lymphocyte antigen CD19 (CD19) and B-cell maturation antigen (BCMA). This dual-targeting approach is designed to enhance efficacy and potentially overcome antigen escape mechanisms in diseases such as relapsed or refractory multiple myeloma. The therapy works by inducing T-cell mediated cytotoxicity against malignant cells that express these specific targets. It is being developed by Suzhou Maximum Bio-tech Co., Ltd. (also known as T-MAXIMUM Biopharmaceuticals (Suzhou) Co., Ltd.).

Targets

CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on CD19-BCMA UCAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19-BCMA UCAR-T.

Explore the full profile